drugset / Press release
Scandion Oncology A/S: Scandion Oncology receives favorable opinion from the European Patent Office on Composition of Matter Patent-application for lead compound SCO-101
2023-01-19 · Scandion Oncology A/S · original scandiononcology.com ↗
The patent would provide protection of the commercial solid form of SCO-101 until at least 2042.
The release as fetched from its publisher. scandiononcology.com ↗